Iron for COVID-19

The World Health Organization has classified the coronavirus disease outbreak as a worldwide pandemic as a result of the COVID-19 expansion. According to medical professionals, individuals with strong immunity often outlive infections more frequently than those with poor immunity. The COVID-19 pandemic has prompted the need for novel approaches to treating the illness and its symptoms. Natural products from plants are increasingly being seen favorably in comparison to synthetic ones in the fight against diseases. As a result, in order to avoid contracting any unanticipated illnesses, individuals must increase their immunity by eating more dietary supplements and by taking drugs that have immune-boosting properties. This review aimed to give a general overview of some traditional Sudanese foods and drinks that are rich in immune-boosting elements, and accordingly, they could be safely recommended as an adjuvant dietary supplement to improve the immune system's ability to fight such infections as COVID-19. Also, this review aims to bring attention to the fact that immune boosters may be found in natural sources, which will help pharmaceutical companies by taking some of the load off of them. Electronic databases, including Google Scholar, Scopus, and the Web of Science, were searched for relevant material. The selected articles underwent independent eligibility and information extraction reviews. The review focused on certain traditional Sudanese herbs and their derivatives that are rich in immune-stimulating vitamins and minerals and therefore could possibly be recommended as immune-boosting dietary supplements to help fight COVID-19. This review highlights the fact that the pharmaceutical sector, especially community and hospital pharmacists, could play a vital role in supporting the healthcare system by encouraging their communities to add plants and their products that are rich in immune-boosting vitamins and minerals to their diet.

Background:The development and roll-out of vaccines, and the use of various drugs have contributed to controlling the COVID-19 pandemic. Nevertheless, challenges such as the inequitable distribution of vaccines, the influence of emerging viral lineages and immune evasive variants on vaccine efficacy, and the inadequate immune defense in subgroups of the population continue to motivate the development of new drugs to combat the disease. Aim:In this study, we sought to identify, prioritize, and characterize drug repurposing candidates appropriate for treating mild, moderate, or severe COVID-19 using a network-based integrative approach that systematically integrates drug-related data and multi-omics datasets. Methods: We leveraged drug data, and multi-omics data, and used a random walk restart algorithm to explore an integrated knowledge graph comprised of three sub-graphs: (i) a COVID-19 knowledge graph, (ii) a drug repurposing knowledge graph, and (iii) a COVID-19 disease-state specific omics graph. Results:We prioritized twenty FDA-approved agents as potential candidate drugs for mild, moderate, and severe COVID-19 disease phases. Specifically, drugs that could stimulate immune cell recruitment and activation including histamine, curcumin, and paclitaxel have potential utility in mild disease states to mitigate disease progression. Drugs like omacetaxine, crizotinib, and vorinostat that exhibit antiviral properties and have the potential to inhibit viral replication can be considered for mild to moderate COVID-19 disease states. Also, given the association between antioxidant deficiency and high inflammatory factors that trigger cytokine storms, antioxidants like glutathione can be considered for moderate disease states. Drugs that exhibit potent anti-inflammatory effects like (i) anti-inflammatory drugs (sarilumab and tocilizumab), (ii) corticosteroids (dexamethasone and hydrocortisone), and (iii) immunosuppressives (sirolimus and cyclosporine) are potential candidates for moderate to severe disease states that trigger a hyperinflammatory cascade of COVID-19. Conclusion:Our study demonstrates that the multi-omics data-driven integrative analysis within the drug data enables prioritizing drug candidates for COVID-19 disease phases, offering a comprehensive basis for therapeutic strategies that can be brought to market quickly given their established safety profiles. Importantly, the multi-omics data-driven integrative analysis within the drug data approach implemented here can be used to prioritize drug repurposing candidates appropriate for other diseases.